Solasta Ventures
Home Approach Portfolio
News Team Hatchery Contact
HomeApproachPortfolio
Solasta Ventures
NewsTeamHatcheryContact
Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial
Nia JulianJune 15, 2021
Facebook0 Twitter Pinterest0 0 Likes
Previous

Xilio Therapeutics Announces FDA Acceptance of IND Application for XTX101 for the Treatment of Solid Tumors

Nia JulianJune 17, 2021
Next

RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial

Nia JulianJune 14, 2021

© 2020 Solasta Ventures. All Rights Reserved.